XML 96 R87.htm IDEA: XBRL DOCUMENT v3.23.3
ACQUISITIONS AND DIVESTITURES - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 12, 2023
Aug. 23, 2023
Sep. 30, 2023
Sep. 30, 2023
Dec. 31, 2022
Aug. 02, 2022
Business Acquisition [Line Items]              
Contract asset $ 68,900     $ 68,900 $ 68,900 $ 0  
Oncotype DX Genomic Prostate Score Test | Disposal Group, Disposed of by Sale, Not Discontinued Operations              
Business Acquisition [Line Items]              
Deferral period for contingent consideration     3 years        
Additional consideration       3,100 3,100    
Contingent consideration, additional outcomes, value high     $ 82,500       $ 70,000
Contingent consideration arrangements, gain (loss)       $ 68,900 $ 68,900    
Developed Technology Rights              
Business Acquisition [Line Items]              
Weighted-average remaining useful life of finite-lived intangible asset (in years) 7 years 6 months     7 years 6 months 7 years 6 months 7 years 9 months 18 days  
Resolution Bioscience              
Business Acquisition [Line Items]              
Total purchase price   $ 54,202          
Cash $ 50,000 $ 52,527          
Payments to be paid to acquire business, gross $ 2,500            
Total fair value of equity awards transferred   4.6 million          
Fair value of replaced equity awards   $ 1,675          
Compensatory portion of equity transferred   2,900          
Developed technology   26,000          
Resolution Bioscience | Developed Technology Rights              
Business Acquisition [Line Items]              
Developed technology   $ 26,000          
Weighted-average remaining useful life of finite-lived intangible asset (in years)   17 years